Dr. Reddy’s Laboratories has announced its consolidated financial results for the third quarter and nine months ended December 31, 2016 under International Financial Reporting Standards (IFRS).
Q3 FY17: Key Highlights
Revenues at Rs. 37.1 billion: QoQ growth: 3%
YoY decline: 7%
Gross Profit Margin at 59.1%.
Research & Development (R&D) spend at Rs. 5.0 billion. [13.4% of Revenues]
Selling, general & administrative (SG&A) expenses at Rs. 11.3 billion [YoY decline: 6%]
EBITDA at Rs. 8.8 billion [23.7% of Revenues]
Profit after tax at Rs. 4.7 billion [12.7% of Revenues]
9M FY17: Key Highlights
Revenues at Rs. 105.3 billion: YoY decline: 10%
Gross Profit Margin at 57.2%.
Research & Development (R&D) spend at Rs. 15.0 billion. [14.2% of Revenues]
Selling, general & administrative (SG&A) expenses at Rs. 35.4 billion [YoY increase: 4%]
EBITDA at Rs. 19.2 billion [18.2% of Revenues]
Profit after tax at Rs. 8.9 billion [8.5% of Revenues]
Commenting on the results, Co-chairman and CEO, G V Prasad said "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs. 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A costs across all our businesses."
All amounts in millions, except EPS
All US dollar amounts based on convenience translation rate of I USD = Rs. 67.92
Dr. Reddy’s Laboratories Limited and Subsidiaries
Consolidated Income Statement
Particulars
Q3 FY17
Q3 FY16
Growth %
($)
(Rs.)
%
($)
(Rs.)
%
Revenue
546
37,065
100.0
584
39,679
100.0
(7)
Cost of revenues
223
15,166
40.9
237
16,089
40.5
(6)
Gross profit
322
21,899
59.1
347
23,590
59.5
(7)
Operating Expenses
Selling, general & administrative expenses
167
11,341
30.6
177
12,039
30.3
(6)
Research and development expenses
73
4,956
13.4
60
4,095
10.3
21
Other operating income
(3)
(187)
(0.5)
(2)
(122)
(0.3)
53
Results from operating activities
85
5,789
15.6
112
7,578
19.1
(24)
Net finance (income) / expense
(1)
(44)
(0.1)
1
62
...
(All Rights Reserved)